These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
417 related items for PubMed ID: 29556838
1. Long-term follow-up of 17 patients with childhood Pompe disease treated with enzyme replacement therapy. van der Meijden JC, Kruijshaar ME, Harlaar L, Rizopoulos D, van der Beek NAME, van der Ploeg AT. J Inherit Metab Dis; 2018 Nov; 41(6):1205-1214. PubMed ID: 29556838 [Abstract] [Full Text] [Related]
2. Long-term benefit of enzyme replacement therapy in Pompe disease: A 5-year prospective study. Kuperus E, Kruijshaar ME, Wens SCA, de Vries JM, Favejee MM, van der Meijden JC, Rizopoulos D, Brusse E, van Doorn PA, van der Ploeg AT, van der Beek NAME. Neurology; 2017 Dec 05; 89(23):2365-2373. PubMed ID: 29117951 [Abstract] [Full Text] [Related]
3. Large variation in effects during 10 years of enzyme therapy in adults with Pompe disease. Harlaar L, Hogrel JY, Perniconi B, Kruijshaar ME, Rizopoulos D, Taouagh N, Canal A, Brusse E, van Doorn PA, van der Ploeg AT, Laforêt P, van der Beek NAME. Neurology; 2019 Nov 05; 93(19):e1756-e1767. PubMed ID: 31619483 [Abstract] [Full Text] [Related]
4. The ACE I/D polymorphism does not explain heterogeneity of natural course and response to enzyme replacement therapy in Pompe disease. Kuperus E, van der Meijden JC, In 't Groen SLM, Kroos MA, Hoogeveen-Westerveld M, Rizopoulos D, Martinez MYN, Kruijshaar ME, van Doorn PA, van der Beek NAME, van der Ploeg AT, Pijnappel WWMP. PLoS One; 2018 Nov 05; 13(12):e0208854. PubMed ID: 30532252 [Abstract] [Full Text] [Related]
5. Effect of enzyme therapy and prognostic factors in 69 adults with Pompe disease: an open-label single-center study. de Vries JM, van der Beek NA, Hop WC, Karstens FP, Wokke JH, de Visser M, van Engelen BG, Kuks JB, van der Kooi AJ, Notermans NC, Faber CG, Verschuuren JJ, Kruijshaar ME, Reuser AJ, van Doorn PA, van der Ploeg AT. Orphanet J Rare Dis; 2012 Sep 26; 7():73. PubMed ID: 23013746 [Abstract] [Full Text] [Related]
8. Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: Prospective analysis from the French Pompe Registry. Semplicini C, De Antonio M, Taouagh N, Béhin A, Bouhour F, Echaniz-Laguna A, Magot A, Nadaj-Pakleza A, Orlikowski D, Sacconi S, Salort-Campana E, Solé G, Tard C, Zagnoli F, Hogrel JY, Hamroun D, Laforêt P, French Pompe Study Group. J Inherit Metab Dis; 2020 Nov 26; 43(6):1219-1231. PubMed ID: 32515844 [Abstract] [Full Text] [Related]
18. Pompe disease: early diagnosis and early treatment make a difference. Chien YH, Hwu WL, Lee NC. Pediatr Neonatol; 2013 Aug 26; 54(4):219-27. PubMed ID: 23632029 [Abstract] [Full Text] [Related]
20. Prognostic factors for the late onset Pompe disease with enzyme replacement therapy: from our experience of 4 cases including an autopsy case. Kobayashi H, Shimada Y, Ikegami M, Kawai T, Sakurai K, Urashima T, Ijima M, Fujiwara M, Kaneshiro E, Ohashi T, Eto Y, Ishigaki K, Osawa M, Kyosen SO, Ida H. Mol Genet Metab; 2010 May 26; 100(1):14-9. PubMed ID: 20202878 [Abstract] [Full Text] [Related] Page: [Next] [New Search]